Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2015 1
2016 1
2020 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Results by year

Filters applied: . Clear all
The following terms were ignored: ), (
Page 1
Pharmacogenetics of anxiety and depression in Alzheimer's disease.
Cacabelos R, Carril JC, Corzo L, Pego R, Cacabelos N, Alcaraz M, Muñiz A, Martínez-Iglesias O, Naidoo V. Cacabelos R, et al. Pharmacogenomics. 2023 Jan;24(1):27-57. doi: 10.2217/pgs-2022-0137. Epub 2023 Jan 11. Pharmacogenomics. 2023. PMID: 36628952 Review.
Anxiety and depression coexist with cognitive impairment in Alzheimer's disease along with other concomitant disorders (>60%), which require multipurpose treatments. ...APOE, CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5, CYP4F2, COMT, MAOB, CHAT …
Anxiety and depression coexist with cognitive impairment in Alzheimer's disease along with other concomitant disorders …
Screening natural inhibitors against upregulated G-protein coupled receptors as potential therapeutics of Alzheimer's disease.
Chaudhary A, Singh V, Varadwaj PK, Mani A. Chaudhary A, et al. J Biomol Struct Dyn. 2022 Feb;40(2):673-684. doi: 10.1080/07391102.2020.1817784. Epub 2020 Sep 9. J Biomol Struct Dyn. 2022. PMID: 32900274
Computational approaches have been helpful in high throughput screening of drug libraries and designing ligands against receptors. Alzheimer's disease is a complex neurological disorder, which causes dementia. ...The objective of this study was to predict ter …
Computational approaches have been helpful in high throughput screening of drug libraries and designing ligands against receptors. Alzhei …
Citalopram for the Treatment of Agitation in Alzheimer Dementia: Genetic Influences.
Peters ME, Vaidya V, Drye LT, Devanand DP, Mintzer JE, Pollock BG, Porsteinsson AP, Rosenberg PB, Schneider LS, Shade DM, Weintraub D, Yesavage J, Lyketsos CG, Avramopoulos D; CitAD Research Group. Peters ME, et al. J Geriatr Psychiatry Neurol. 2016 Mar;29(2):59-64. doi: 10.1177/0891988715601735. Epub 2015 Aug 23. J Geriatr Psychiatry Neurol. 2016. PMID: 26303700 Free PMC article. Clinical Trial.
METHOD: We utilized data from the Citalopram for Agitation in Alzheimer's Disease (CitAD) database. CitAD was a 9-week randomized, double-blind, placebo-controlled multicenter clinical trial showing significant improvement in agitation and caregiver distress …
METHOD: We utilized data from the Citalopram for Agitation in Alzheimer's Disease (CitAD) database. CitAD was a 9-week …
Sertraline for the treatment of depression in Alzheimer disease: genetic influences.
Peters ME, Vaidya V, Drye LT, Rosenberg PB, Martin BK, Porsteinsson AP, Frangakis CE, Mintzer J, Weintraub D, Schneider LS, Rabins PV, Munro CA, Meinert CL, Lyketsos CG, Avramopoulos D; DIADS-2 Research Group. Peters ME, et al. J Geriatr Psychiatry Neurol. 2011 Dec;24(4):222-8. doi: 10.1177/0891988711422527. J Geriatr Psychiatry Neurol. 2011. PMID: 22228829 Free PMC article.
Treatment response by genotype was measured by (1) the modified Alzheimer's Disease Cooperative Study Clinical Global Impression of Change, (2) the Cornell scale for Depression in Dementia, and (3) remission of depression. METHODS: We utilized data from the D …
Treatment response by genotype was measured by (1) the modified Alzheimer's Disease Cooperative Study Clinical Global I …